Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
NCT02584777 · Baxalta now part of Shire · PHASE2 · withdrawn · last registry update 2021-05-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Baxalta now part of Shire |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-02Phase 3 first posted: LEO Pharma, Delgocitinib + Cream vehicle (NCT05355818)
- 2022-04-13Phase 3 first posted: University of Texas Southwestern Medical Center, Tofacitinib 10mg + Temozolomide (NCT05326464)
- 2022-03-31Results posted on the registry: AbbVie, Placebo + Upadacitinib (NCT03568318)
- 2022-03-28Results posted on the registry: AbbVie, Placebo for Upadacitinib + Upadacitinib (NCT03607422)
- 2022-02-03Results posted on the registry: AbbVie, Placebo for Upadacitinib + Upadacitinib (NCT03569293)
- 2021-10-12Phase 3 first posted: Eli Lilly and Company, Baricitinib (NCT05074420)
- 2021-09-24Phase 3 first posted: Incepta Pharmaceuticals Ltd, Baricitinib + Placebo (NCT05056558)
- 2021-07-22Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Baricitinib + Placebo (NCT04972760)
- 2021-05-04Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Rituximab + Tocilizumab (NCT04871191)
- 2021-05-03Phase 3 first posted: University Hospital, Bordeaux, baricitinib treatment + anti-TNF therapy (NCT04870203)
- 2020-12-31Phase 3 first posted: University of Alabama at Birmingham, targeted synthetic DMARD class + non-TNFi-biologic class (NCT04692493)
- 2020-11-10Phase 3 first posted: Pfizer, tofacitinib (NCT04624230)
- 2020-10-26Phase 3 first posted: Novartis Pharmaceuticals, Pelabresib + Ruxolitinib (NCT04603495)
- 2020-09-24Phase 3 first posted: Karyopharm Therapeutics Inc, Selinexor + Selinexor (NCT04562389)
- 2020-07-15Phase 3 first posted: AbbVie, Placebo for Navitoclax + Ruxolitinib (NCT04472598)
- 2020-07-13Phase 3 first posted: AbbVie, Navitoclax + Ruxolitinib (NCT04468984)
- 2020-05-11Phase 3 first posted: University of Oxford, Lopinavir-Ritonavir + Corticosteroid (NCT04381936)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision